Risk factors of serious infections in patients with large-vessel vasculitis after the approval of tocilizumab in 2017: a retrospective nested case-control study using the Japanese health insurance dat
4 hours ago
- #serious infection
- #tocilizumab
- #large-vessel vasculitis
- Study examines risk factors of serious infections in large-vessel vasculitis patients post-tocilizumab approval in 2017.
- Retrospective nested case-control study using Japanese health insurance database.
- Key focus on large-vessel vasculitis, including Takayasu arteritis and giant cell arteritis.
- Ethics approval obtained from Meiji Pharmaceutical University.
- Multiple authors report competing interests, including grants and speaker fees from pharmaceutical companies.
- References include studies on pathophysiology, epidemiology, and treatment outcomes of large-vessel vasculitis.